Cargando…

Treatment Patterns of Real-World Patients with TRK Fusion Cancer Treated by US Community Oncologists

BACKGROUND: Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are present across various tumor types with an estimated overall prevalence of less than 1%. Tropomyosin receptor kinase inhibitors (TRKis) block the constitutively activated tyrosine receptor kinase (TRK) fusion protein produced...

Descripción completa

Detalles Bibliográficos
Autores principales:	Klink, Andrew J, Kavati, Abhishek, Gassama, Awa, Kozlek, Tom, Gajra, Ajeet, Antoine, Ruth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512741/ https://www.ncbi.nlm.nih.gov/pubmed/36089643 http://dx.doi.org/10.1007/s11523-022-00909-7

Ejemplares similares

Timing of NTRK Gene Fusion Testing and Treatment Modifications Following TRK Fusion Status Among US Oncologists Treating TRK Fusion Cancer
por: Klink, Andrew J., et al.
Publicado: (2022)

A Letter in Support of Real-World RECIST
por: Gajra, Ajeet, et al.
Publicado: (2020)

Impact of social determinants of health on cancer care: a survey of community oncologists
por: Zettler, Marjorie E, et al.
Publicado: (2021)

Expanded Access and Right To Try Requests: The Community Oncologist's Experience
por: Zettler, Marjorie E., et al.
Publicado: (2021)

TRK Fusion Cancer: Patient Characteristics and Survival Analysis in the Real-World Setting
por: Bazhenova, Lyudmila, et al.
Publicado: (2021)

Low Rate of Clinically Evident Extravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with a Complement C5 Inhibitor: Results from a Large, Multicenter, US Real-World Study
por: Shammo, Jamile, et al.
Publicado: (2022)

Comparative Effectiveness of Palliative Chemotherapy in Metastatic Breast Cancer: A Real‐World Evidence Analysis
por: Feinberg, Bruce, et al.
Publicado: (2020)

TRK inhibitors in TRK fusion-positive cancers
por: Drilon, A
Publicado: (2019)

P1157: REAL-WORLD TREATMENT PATTERNS AND COMPARATIVE EFFECTIVENESS OF BRUTON TYROSINE KINASE INHIBITORS IN PATIENTS WITH MANTLE CELL LYMPHOMA
por: Shah, B., et al.
Publicado: (2022)

Characteristics, Treatment, and Outcomes of Real-World Talazoparib-Treated Patients With Germline BRCA-Mutated Advanced HER2-Negative Breast Cancer
por: Savill, Kristin M Zimmerman, et al.
Publicado: (2023)

Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib
por: Yang, James C. H., et al.
Publicado: (2022)

Indirect Treatment Comparison of Larotrectinib versus Entrectinib in Treating Patients with TRK Gene Fusion Cancers
por: Garcia-Foncillas, Jesus, et al.
Publicado: (2022)

Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers
por: Chen, Yu, et al.
Publicado: (2018)

Differential impact of cognitive computing augmented by real world evidence on novice and expert oncologists
por: McNamara, Donna M., et al.
Publicado: (2019)

Cost-effectiveness of twice-daily indacaterol/glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US
por: Rajagopalan, Krithika, et al.
Publicado: (2018)

Impact of Augmented Intelligence on Utilization of Palliative Care Services in a Real-World Oncology Setting
por: Gajra, Ajeet, et al.
Publicado: (2022)

TRK inhibitors block NFKB and induce NRF2 in TRK fusion-positive colon cancer
por: Sohn, Sung-Hwa, et al.
Publicado: (2021)

Assessing Oncologists’ Adoption of Biomarker Testing in Metastatic Colorectal Cancer Using Real-World Data
por: Iyer, Pritish, et al.
Publicado: (2022)

P515: A REAL-WORLD EVALUATION OF TREATMENT PATTERNS AND OUTCOMES OF ACUTE MYELOID LEUKEMIA INDUCTION THERAPIES IN THE COMMUNITY SETTING
por: Maher, Keri, et al.
Publicado: (2023)

Real-World Characteristics and Treatment Patterns in Patients with Urticaria Initiating Omalizumab in the United States
por: Ke, Xuehua, et al.
Publicado: (2018)

Biosimilars 101: considerations for U.S. oncologists in clinical practice
por: Camacho, Luis H, et al.
Publicado: (2014)

Comparison of Solid Tumor Treatment Response Observed in Clinical Practice With Response Reported in Clinical Trials
por: Feinberg, Bruce A., et al.
Publicado: (2021)

Current Status of New Anticoagulants in the Management of Venous Thromboembolism
por: Montoya, Roberto C., et al.
Publicado: (2012)

Testing algorithm for identification of patients with TRK fusion cancer
por: Penault-Llorca, Frédérique, et al.
Publicado: (2019)

Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network
por: Demetri, G. D., et al.
Publicado: (2020)

Traveling With Cancer: A Guide for Oncologists in the Modern World
por: Heng, Sharon, et al.
Publicado: (2019)

PB1926: REAL-WORLD ERYTHROPOIESIS-STIMULATING AGENT (ESA) TREATMENT PATTERNS AND OUTCOMES AMONG US PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS)
por: Mukherjee, S., et al.
Publicado: (2022)

Real-world Treatment Patterns and Reasons for Therapy Selection in Patients with Advanced Hepatocellular Carcinoma in US Oncology Practices
por: Klink, Andrew J, et al.
Publicado: (2022)

Real-World Breast Cancer Patient Follow-Up Practices by Medical Oncologists in India—A Survey Report
por: Patel, Amol, et al.
Publicado: (2022)

Real-world survival outcomes in patients with locally advanced or metastatic NTRK fusion-positive solid tumors receiving standard-of-care therapies other than targeted TRK inhibitors
por: Hibar, Derrek P., et al.
Publicado: (2022)

Methods for Identifying Patients with Tropomyosin Receptor Kinase (TRK) Fusion Cancer
por: Wong, Derek, et al.
Publicado: (2019)

Larotrectinib Demonstrates CNS Efficacy in TRK Fusion-Positive Solid Tumors
por: Rosen, Ezra Y., et al.
Publicado: (2019)

NTRK Fusions and TRK Inhibitors: Potential Targeted Therapies for Adult Glioblastoma
por: Wang, Yuekun, et al.
Publicado: (2020)

Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults †
por: Bebb, D. Gwyn, et al.
Publicado: (2021)

Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma
por: Waguespack, Steven G, et al.
Publicado: (2022)

Applicability of pan-TRK immunohistochemistry for identification of NTRK fusions in lung carcinoma
por: Strohmeier, Simon, et al.
Publicado: (2021)

TRK Protein Expression in Merkel Cell Carcinoma Is Not Caused by NTRK Fusions
por: Cappellesso, Rocco, et al.
Publicado: (2022)

Prevalence and clinico-genomic characteristics of patients with TRK fusion cancer in China
por: Xu, Yujun, et al.
Publicado: (2023)

PET Response-Guided Treatment of Hodgkin's Lymphoma: A Review of the Evidence and Active Clinical Trials
por: Aridgides, Paul, et al.
Publicado: (2011)

Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291)
por: Saad, Nibal, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_upcsgn8759hoc5ucge4tmni0b8